Alerta

Smart Footwear, Insoles or Other Wearables with Electronically Read Sensing Membrane and Self-Identification of Left/Right Status

Resumen de: US20260198800A1

Wearable smart devices are disclosed that incorporate a unique means of detecting or measuring a substance of interest, for example to detect ammonia in the secreted foot sweat of a diabetic via incorporation of the sensing arrangement in a footwear article or insole. The setup employs the combination of a colour-changing sensing membrane responsive to the substance of interest, an optical sensor appropriately positioned to capture the membrane within its field of view, and an illumination means for illuminating the membrane to enable optical imaging thereof, from which a controller can then detect the colour of the membrane and determine the presence or measurement of the substance of interest. A left/right self-identification circuit is included in each wearable smart device to enable a cooperative pair of such devices, worn on different bilateral appendages, to self-identify their left/right designation to the external device that receives the outputted signals from the wearables.

METHOD OF INDUCING UMBILICAL CORD MESENCHYMAL STEM CELLS TO DIFFERENTIATE INSULIN-LIKE CELLS AND AN APPLICATION THEREOF

Resumen de: US20260201338A1

A method of inducing umbilical cord mesenchymal stem cells to differentiate insulin-like cells and an application thereof, the invention carries out reasonable culture of purified umbilical cord mesenchymal stem cells by adopting culture medium having different substances, and can efficiently and stably induce them to differentiate into insulin-like cells, and the percentage of insulin-positive cells can reach 80%. The cell preparation prepared after induction of umbilical cord mesenchymal stem cells of the invention can be used for the treatment of clinical diabetic patients with high therapeutic efficacy.

GLUCOSE LEVEL INDICATOR MODEL WITH MODIFIED ERROR RATE

Resumen de: US20260198867A1

A system is described herein comprising at least one application running on one or more processors of a server, wherein the at least one application is communicatively coupled with one or more sensor devices and a remote mobile device, the one or more sensor devices configured to monitor real time biometric data of a subject, the one or more sensing devices configured to transmit the real time biometric data to the at least one application, the at least one application configured to extract feature data variables from the real time biometric data, apply a predictive model to the feature data variables to predict glucose levels of the subject over a future period of time, and communicate a signal to the mobile device when predicted glucose levels cross either an upper or lower threshold.

METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS

Resumen de: WO2026151664A1

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and/or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

INSULIN PEN-TYPE SYRINGE REFRIGERATION CUP

Resumen de: US20260199610A1

0000 An insulin pen-type syringe refrigeration cup is provided, which is provided with an insulin pen cartridge. The insulin pen-type syringe refrigeration cup includes a refrigeration component, a cold conduction tube, a cup lid, and a cup body. The cold conduction tube defines a storage space that accommodates insulin pens, the storage space is also suitable for accommodating the insulin pen cartridge. A diameter of the cold conduction tube is 20 mm-50 mm. The cold conduction tube includes an avoidance groove. The cup lid is suitable for accommodating the refrigeration component. The cup body includes a cup wall and an insulation chamber. The cup lid can detachably seal the insulation chamber, and the refrigeration component keeps the insulation chamber in a low temperature state. The present disclosure significantly reduces the volume by limiting the size of the cold conduction tube and providing the avoidance groove.

WEARABLE DUAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS FOR PRECISION DIABETES MANAGEMENT

Resumen de: US20260199601A1

0000 A wearable dual closed-loop insulin delivery system is provided that integrates both a chemical closed-loop and an electronic closed-loop for precise glycemic control. The system includes a continuous glucose monitor (CGM) configured to obtain real-time blood glucose concentrations of a subject, and a glucose-responsive insulin (GRI) delivery device containing a GRI formulation that autonomously modulates its insulin-release rate in response to the subject's glucose levels, thereby forming a chemical closed-loop. The system further includes a controller having one or more computer processors executing a machine-learning adaptive glucose forecasting model with an Encoder-Decoder architecture. The model receives real-time glucose measurements from the CGM, predicts glycemia dynamics for at least a time period (i.e., 30 minute) future interval, and generates dosing-control signals to adjust both insulin-dosing amount and timing, forming an electronic closed-loop. The controller is operatively connected to the CGM and the GRI delivery device, enabling predictive, automated insulin regulation.

METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS

Resumen de: US20260201339A1

0000 Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

GLUCOSE MONITORING

Resumen de: US20260198807A1

0000 A light source is tuned to a range of wavelengths selected for relatively high absorption by glucose, while an optical sensor uses a complementary filter that selectively absorbs in the same spectrum. This optical channel, in combination with a separate, unfiltered reference optical channel, supports a calculation of glucose concentration in target tissue based on a ratiometric comparison of measured light intensities. In embodiments, quantum dots or other techniques can be used to tune the optical spectrum of a light source, while glucose or a similarly absorbing material can be embedded in an optical potting material or the like to create a similarly tuned filter for a corresponding optical sensor. The supporting hardware may usefully be deployed in a wearable physiological monitor for continuous monitoring of glucose (or other target molecules) in the tissue of a user.

ADVANCED CONTINUOUS ANALYTE MONITORING SYSTEM

Resumen de: EP4776527A2

The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.

LINEAR TIME-VARYING MODEL PREDICTIVE CONTROL OF AN ARTIFICIAL PANCREAS WITH BLOOD GLUCOSE PREDICTORS

Resumen de: WO2025054131A1

A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.

DEVICE FOR COLLECTION OF VOLATILE COMPOUNDS FROM SKIN FOR NON-INVASIVE MEASUREMENT OF BLOOD-GLUCOSE VALUES

Resumen de: WO2021167918A1

A volumetric sampling apparatus for volatile compounds comprises a structure, such as a channel structure that forms a continuous curve between the inlet port and the outlet port. A gas flow induced in the structure urges volatile compounds collected via transdermal diffusion toward the outlet port, where the volatile compounds may be collected and analyzed.

SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS

Resumen de: US20260192043A1

0000 Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.

HCG TUNABLE VCSEL WITH OPTICAL CONFINEMENT VIA STEP INDEX AND REGROWTH

Resumen de: US20260196807A1

A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a wearable device interior houses the VCSEL laser.

SYSTEMS AND METHODS FOR USING CONTINUOUS KETONE MONITORING TO PROVIDE FITNESS OPTIMIZATION AND DISEASE DIAGNOSIS

Resumen de: WO2026147609A1

Certain aspects of the present disclosure provide a therapy management system configured to monitor analyte levels of a host during a time period using one or more analyte sensors to obtain analyte data, the analyte levels comprising at least glucose levels and ketone levels, and determine a metabolic fitness of the host based, at least in part, on the analyte data. The therapy management system is further configured to provide therapy management guidance to the host based, at least in part, on the determined metabolic fitness to improve the metabolic fitness of the host. The therapy management guidance includes at least one of a diet or meal recommendation for the host, an exercise recommendation for the host, or a lifestyle recommendation for the host.

HEALTH EDUCATION-INTEGRATED LAUGHTER YOGA EXERCISE INTERVENTION TRAINING METHOD FOR DIABETIC FOOT PATIENTS

Resumen de: LU604632B1

The present invention provides a health education-integrated laughter yoga exercise intervention training method for diabetic foot patients, including: acquiring, in real time, multimodal physiological data of the patient including foot physiological parameters, systemic physiological indicators, and laughter audio signals; determining the patient’s current physiological context in real time based on the data, and dynamically generating a comprehensive intervention strategy; the strategy includes laughter yoga exercise instructions, context-embedded health education content, distributed proprioceptive guidance instructions for real-time posture adjustment guidance, and acoustic resonance induction instructions for emotional regulation; executing the strategy, and performing adaptive adjustment on the decision-making model for generating the strategy according to changes in physiological data after intervention. By constructing a closed-loop system of sensing, decision-making, execution, and feedback, the present invention is capable of providing patients with personalized, safe and dynamically adaptive rehabilitation training programs, achieving the coordinated rehabilitation of physical and psychological states.

Multi-State Engagement With Continuous Glucose Monitoring Systems

Resumen de: US20260191434A1

Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148093A1

Techniques for improved respiratory therapy are provided. Glucose data of a user, collected while the user was awake, is accessed, where the user is a participant in a respiratory therapy. A metabolic health (MH) state of the user is determined based at least in part on the glucose data. A respiratory therapy configuration for a subsequent usage session of the user is generated based on evaluating the MH state using one or more MH models. A respiratory therapy flow generator of the user is instructed to implement the respiratory therapy configuration during a usage session.

MEDICAMENT DELIVERY SYSTEM USING LACTATE DATA

Resumen de: WO2026147654A1

A method of delivering a medicament to a subject for the treatment of diabetes includes: receiving glucose data and lactate data for the subject; adjusting medicament therapy to be delivered to the subject based at least in part on the glucose data and the lactate data; and delivering the adjusted medicament therapy to the subject.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148099A1

Techniques for improved respiratory therapy are provided. Glucose data of a user collected during a sleep session is accessed. Based at least in part on the glucose data, a plurality of transitions between sleep stages experienced by the user during the sleep session is determined. A sleep quality measure for the sleep session is generated based at least in part on the plurality of transitions. An apnea risk score for the user is generated based at least in part on the sleep quality measure, and one or more medical interventions for the user are provided based on the apnea risk score.

ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOF

Resumen de: AU2026204844A1

The present invention relates to variants of acid-alpha glucosidase and uses thereof. un u n

MITIGATION OF COMPRESSION EVENT FAILURE FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: AU2024395288A1

Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.

SYSTEMS, DEVICES, AND METHODS FOR MEAL INFORMATION COLLECTION, MEAL ASSESSMENT, AND ANALYTE DATA CORRELATION

Resumen de: US20260191433A1

Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Various embodiments disclosed herein relate to methods, systems, and software applications intended to engage an individual by providing direct and timely feedback regarding the individual's meal-related glycemic response.

SYSTEM AND METHOD FOR TITRATING BASAL INSULIN DOSES

Resumen de: US20260192048A1

0000 A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

GLUCOSE LEVEL DEVIATION DETECTION

Resumen de: US20260191435A1

0000 Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

A NEW SITE FOR TRANSPLANTATION

Nº publicación: US20260191912A1 09/07/2026

Solicitante:

HANGZHOU REPROGENIX BIOSCIENCE INC [CN]
HANGZHOU REPROGENIX BIOSCIENCE, INC.

Resumen de: US20260191912A1

Methods for transplanting cells or tissues, in particular islets, into a sub-rectus sheath site. Methods for treating diabetes by transplanting islets, particularly hPSC-islets, into a sub-rectus sheath position. The sub-rectus sheath position is a new site for transplantation.